Disease-free survival | Overall survival | ||||
---|---|---|---|---|---|
Factor | Number of patients (%) | P | RR (95% CI) | P | RR (95% CI) |
Menopausal status (n = 209) | |||||
Premenopausal | 62 (29.7) | 0.121 | 1.73 (0.86–3.47) | 0.061 | 2.49 (0.96–6.45) |
Postmenopausal | 147 (70.3) | ||||
Histological grading (n = 206) | |||||
I | 101 (49.0) | 0.113 | 1.36 (0.93–2.0) | 0.003 | 1.93 (1.25–3.0) |
II | 81 (39.3) | ||||
III | 24 (11.7) | ||||
Lymph node status (n = 203) | |||||
Negative | 116 (57.1) | 0.009 | 2.22 (1.22–4.03) | 0.095 | 1.85 (0.9–3.82) |
Positive | 88 (42.9) | ||||
Tumour size (n = 205) | |||||
pT1 | 93 (45.4) | 0.001 | 1.85 (1.29–2.65) | <0.001 | 2.3 (1.53–3.45) |
pT2 | 96 (46.8) | ||||
pT3 and pT4 | 16 (7.8) | ||||
Oestrogen receptor status (n = 208) | |||||
≤ 10 fmol/mg | 74 (35.6) | 0.73 | 1.12 (0.58–2.16) | 0.547 | 1.29 (0.56–2.99) |
>10 fmol/mg | 134 (64.4) | ||||
Progesterone receptor status (n | = 205) | ||||
≤ 10 fmol/mg | 118 (57.6) | 0.056 | 0.57 (0.33–1.01) | 0.636 | 0.84 (0.42–1.67) |
>10 fmol/mg | 87 (42.4) | ||||
Fas ligand : Fas ratio (n = 211) | |||||
≤ 1 | 139 | 0.023 | 1.92 (1.09–3.35) | 0.172 | 1.61 (0.81–3.2) |
>1 | 72 |